← SynDRA
BELUMOSUDIL
SynDRA canonical compound SYN0028910 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ROCK2 |
|---|
| Mechanism of action | rho associated kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- ROCK2 INHIBITOR
- Rho-associated protein kinase 2 inhibitor
- ROCK1 INHIBITOR
- rho associated kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AKT1
- MINK1
- PIM3
- PIM2
- PIM1
- PHKG2
- PDPK1
- PAK4
- PAK1
- NTRK3
- NTRK2
- NTRK1
- NEK4
- NEK2
- MKNK2
- MET
- MAP4K2
- MELK
- MATK
- MARK3
- MARK2
- MAPKAPK5
- MAPKAPK3
- MAPKAPK2
- MAPK9
- MAPK8
- MAPK13
- MAPK12
- MAPK1
- MAP4K5
- PKN2
- PLK4
- PRKAA1
- PRKACA
- TYK2
- TSSK2
- TSSK1B
- TAOK1
- SYK
- STK3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP2D6
- CP3A7
- CSK21
- DYR1A
- IFNG
- NSD2
- PARP1
- ST17A
Drug classes
- Enzyme Inhibitors
- Protein Kinase Inhibitors
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- REZUROCK
- Rezurock
- belumosudil mesylate
- rezurock
- KD025
- SLx-2119
- Rock2 inhibitor kd025
- Slx-2119 free base
- KD-025
- SLx 2119
- KD 025
- ROCK inhibitor 2
- Belumosudil [USAN]
- SLx2119
- 834YJF89WO
- C26H24N6O2
- KD025 (SLx-2119)
- SLx-2119(KD-025)
- UNII-834YJF89WO
- Kinome_2597
- BELUMOSUDIL [INN]
- BELUMOSUDIL [WHO-DD]
- SCHEMBL878202
- GTPL9558
- CHEMBL2005186
- DTXSID80238425
- BDBM322155
- BDBM435505
- BCP15921
- EX-A2314
- MFCD23098791
- s7936
- WHO 11343
- ZINC63298464
- SLx-2119; KD-025
- US10570123, Example 232
- CCG-269256
- CS-0776
Reported adverse events
- Abdominal pain
- Arthralgia
- Asthenia
- Clostridium difficile colitis
- Cough
- Dysphagia
- Epstein-Barr virus infection
- Headache
- Hypertension
- Infection
- Musculoskeletal pain
- Nasal congestion
Look up BELUMOSUDIL in the interactive SynDRA portal →